Spring 2023 LipidSpin Articles

Kevin C. Maki, PhD, CLS, FNLA*

Letter from the NLA President: Exciting Year Ahead!

Hello fellow NLA members, Happy New Year! I hope everyone had a restful and happy holiday season. I look forward to celebrating the many incredible projects the NLA is executing in 2023, one being this SWLA/PLA LipidSpin. I hope you walk away after reading this with inspiration in your heart and new, helpful lipid science in your pocket. The NLA has gained traction and made immense impact over its short 20-year existence, but there is always more to be learned, explored, and applied... more

Lynne T. Braun, PhD, CLS, FNLA*

Editor's Corner: Missed Opportunities

Happy New Year to All! On behalf of co-editor Dr. Kaye-Eileen Willard and myself, I wish to thank those of you who have contributed to the outstanding issues of LipidSpin during the last year and look forward to the education and clinical insights provided by NLA members in 2023. I’m excited about the articles of this issue, centered on the theme Pushing Boundaries. I also thank the Presidents and Board members of the Southwest and Pacific Lipid Associations for their leadership.... more

Nicole Ciffone, ANP-C, MS, CLS, FNLA*

Letter from the SWLA President: New Horizons, New Possibilities

Visionary. Pioneer. Trailblazer. Inventor. Innovator. Boundary pusher. Those who push past what is for what can be.

Pushing Boundaries, the theme for this edition of LipidSpin, was inspired and informed by our members and members of the lipid community as we collectively move past a time of challenges, separation, and limitations caused by the COVID-19 pandemic. I believe we now have an opportunity for expansion and growth that is clearly evident in our... more

Michelle Taylor, MSN, ACNP-BC, CLS, FNLA*

Letter from the PLA President: Paving a Healthier Path

“The problem with heart disease is that the first symptom is often fatal.”  - Michael Phelps

As an Acute Care Nurse Practitioner specializing in cardiac surgery and interventional cardiology, I have heard far too often from my patients with acute coronary syndrome, as they were in transit to the interventional lab or surgical suite, “I had no idea I had heart disease.” Hearing this phrase from patients at a critical moment in their lives, compelled me to seek the necessary... more

Michael J. Wilkinson, MD, FACC*
Elizabeth J. Jackson, ACNS-BC, DipACLM, CCHP CLS, FNLA*
Elizabeth M. Urteaga, PharmD, BC-ADM
Lauren Williams, MCN, RDN, LD

Clinical Feature: How We Do It: Lipid Specialists Pushing Boundaries to Improve Patient Care Across a Variety of Practice Settings

The NLA now includes > 2,000 members with representation from physicians, NP/PAs, clinical pharmacists, dietitians, and other healthcare professionals. In this Clinical Feature, we highlight the many ways in which our SWLA/PLA members are pushing boundaries in Clinical Lipidology. Across the NLA, professionals of diverse backgrounds share many goals and are all working together to advance this important field:

  • We provide expert care in lipidology and CVD prevention. ... more
Mutaz Al-Khnifsawi, MD
Raul D. Santos, MD, PhD

Guest Editorial: Fighting the Impossible!

“If we wait for the appropriate time to start working, we shall never work; it is better to start with the available means and let the next generation continue what we started”. - Mutaz Al-Khnifsawi, MD


Familial hypercholesterolemia (FH) is a common genetic lipid disorder. Due to the high level of consanguinity in MENA (Middle-East North-Africa) in particularly Arabic countries, this genetic lipid disorder is increasing... more

Brian Cheung, MD
Ian Riddock, MD, FACC*
Ailin Barseghian El-Farra, MD, FACC
Lane Benes, MD, FACC*

EBM Tools for Practice: Improving Lipid Management for the Acute Coronary Syndrome Patient


It’s been over 20 years since the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial1 ushered in the initiation of aggressive LDL-C lowering therapy before hospital discharge for acute coronary syndrome (ACS). Three years later, the Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (PROVE-IT TIMI 22) trial2 demonstrated the superiority of high-intensity lowering over... more

Rishi Rikhi, MD
Harpreet Bhatia, MD, MAS, FACC

Lipid Luminations: Aspirin Use and Lipoprotein(a) Genotypes in Primary Prevention

Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Although approximately 20% of the population has elevated Lp(a) levels (≥ 50 mg/dL or 125 nmol/L), there are currently no approved targeted medical treatments available. Lp(a) has a unique structure, similar to low-density lipoprotein-cholesterol, with an additional apolipoprotein(a) component, evolved from plasminogen. This structure is associated with proatherogenic, proinflammatory,... more

Priyanka Satish, MD
Sherwin D’Souza, MD, FACE*
Anandita Agarwala, MD

Practical Pearls: When Is It Reasonable to Consider Withholding Lipid Lowering Therapy?

Lipid lowering therapy is a cornerstone of cardiovascular risk reduction. However, withholding or stopping lipid lowering therapy may be worth consideration in some individuals. These include elderly patients with comorbidities limiting life expectancy, individuals with a coronary artery calcium score of 0 (CAC =0), patients with end stage renal disease (ESRD), and pregnant and lactating women. This review will discuss these scenarios.

Primary Prevention in Elderly Patients... more

Diane Obsorn, MN, ANP, CLS, FNLA*
Chima Nwizu, MD, FAAFP, FOMA, FNLA*

Specialty Corner: Pharmacotherapy in Obesity: Not Just for Three Months

Overweight and obesity rates continue to climb worldwide, contributing to significant morbidity and mortality, despite several effective pharmacotherapy treatments that are grossly underutilized. Obesity is a major health problem with a US prevalence of 42.4% in adults and 19.3% in children.1 It was first recognized as a disease in 1948 by the World Health Organization.2 The National Institute of Health recognized obesity as a disease3 in 1998, and in 2004,... more

Josh Peedikayil
Zahid Ahmad, MD, FNLA*

Population Study: Lipid Treatment for Uninsured Populations with Severe Hypercholesterolemia

The characterization and treatment of severe hypercholesterolemia among patients within large health systems have been studied extensively.1-6 However, little is known about the burden of disease at charity based or community clinics. These types of clinics often provide care for underserved, uninsured populations who are unable to access care even from safety-net healthcare systems.7-9 An estimated 26 million uninsured patients rely on one of 1,400 charity/community... more

Geeta Sikand, RDN, FAND, CDE, CLS, FNLA*

PLA Chapter Update: Moving Forward Together!

As President-Elect of the Pacific Lipid Association (PLA), I am super excited to share with you that the 2023 year is off to a great start! This issue of LipidSpin is a collaboration between PLA and SWLA with a focus on Pushing Boundaries. My immense gratitude goes out to all who have contributed. 

I hope all members of the NLA are enjoying the Pentathlon Challenge. You could earn your PLA some points by following the link lipid.org/pentathlon and participating in the... more

Kevin Forey, MD, MBA

SWLA Chapter Update: Hard Work Pays Off!

The Southwest Lipid Association (SWLA) would like to thank all the contributing authors and editors for another edition of LipidSpin. Most importantly, SWLA and its board would like to thank all NLA members for their contributions, pushing boundaries, promoting healthier communities, and fostering greater awareness of Clinical Lipidology. 

As the world continues to move forward from the restraints and restrictions of the coronavirus pandemic, we find tremendous inspiration... more

Member Spotlight: Lipid Scholarship Program Recipients

Dr. Scott Kirkpatrick is SWLA’s 2022 Lipid Scholarship Program recipient, a PGY-5 cardiology fellow at the University of Arizona-Tuscon. As a future general cardiologist with a passion for preventive cardiology, his career mission is to help as many people as he can in the fight against cardiovascular disease, the number one reason loved ones are lost and our one... more

*NEW* 2023 Spring WordSpin

New to LipidSpin! Post your completed crossword on social media and tag @nationallipid on Twitter, Facebook, and Instagram! If you are participating in the Pentathlon Challenge, you will earn 60 points for your social post!

Click here to download the 2023 Spring WordSpin Crossword.pdf

... more

NLA News and Notes

The NLA is excited to announce the Pentathlon Challenge, as we “Aim for Atlanta” and the 2023 Scientific Sessions. The Pentathlon Challenge is Olympic-inspired and consists of free and for-purchase activities from January 1, 2023, through June 1, 2023. The Pentathlon (5 months) will engage members through a variety of both CME/CE and non-CME/CE live and on-demand activities. Participation in an activity will award... more